An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.

Nanfang Hospital, Southern Medical University0 sites13 target enrollmentDecember 31, 2024

ConditionsAdvanced Colorectal Adenocarcinoma

InterventionsDoxorubicin liposome combined with CapOX and Bevacizumab

DrugsDoxorubicin liposome combined with CapOX and Bevacizumab

Overview

Phase: Phase 1
Intervention: Doxorubicin liposome combined with CapOX and Bevacizumab
Conditions: Advanced Colorectal Adenocarcinoma
Sponsor: Nanfang Hospital, Southern Medical University
Enrollment: 13
Primary Endpoint: 6-month progression-free survival (PFS)
Status: Not yet recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

This is a prospective, single-arm clinical study designed to evaluate the 6-month progression-free survival rate (6-month PFS rate) of Doxorubicin liposome combined with CapOX and Bevacizumab regimen as first-line treatment for advanced colorectal adenocarcinoma with SMAD4R361H/C mutation. The study plans to recruit 13 patients. After receiving 8 cycles of induction therapy, patients whose efficacy is evaluated as complete response (CR), partial response (PR), or stable disease (SD) (according to RECIST 1.1) will enter maintenance therapy.

Registry

clinicaltrials.gov

Start Date

December 31, 2024

End Date

June 1, 2027

Last Updated

last year

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Nanfang Hospital, Southern Medical University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•The patient voluntarily participates in the study, signs the informed consent form, and demonstrates good compliance;
•Age 18 years or older (inclusive), regardless of gender;
•Histologically and/or cytologically confirmed unresectable colorectal adenocarcinoma;
•For left-sided colon cancer or rectal cancer patients, must be non-RAS wild-type;
•Non-dMMR/MSI-H;
•SMAD4R361H/C mutation;
•No prior history of systemic chemotherapy;
•ECOG performance status of 0 or 1;
•Hematological tests (within 14 days without blood transfusion): neutrophil absolute count ≥ 1.5 × 10⁹/L, platelet count ≥ 100 × 10⁹/L, hemoglobin ≥ 90 g/L;
•Liver function tests (AST and ALT ≤ 3 × ULN, bilirubin ≤ 1.5 × ULN; if liver metastasis is present, AST and ALT ≤ 5 × ULN);

Exclusion Criteria

•Patients with known contraindications to Doxorubicin liposome, Oxaliplatin, Capecitabine, or Bevacizumab;
•Patients who have received radiotherapy or any anti-tumor treatments (chemotherapy, targeted therapy, immunotherapy, radiofrequency ablation, traditional Chinese medicine with anti-tumor indications, immunomodulators, or tumor embolization, etc.);
•Patients who have had other malignancies within the past 5 years or have concurrent malignancies (except for cured skin basal cell carcinoma and carcinoma in situ of the cervix);
•Patients who have experienced significant clinical bleeding symptoms, obvious bleeding tendency, or hemoptysis within 3 months prior to treatment, or who have had venous/thrombotic events such as cerebrovascular accidents (including transient ischemic attacks, intracerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism within the previous 6 months; or require long-term anticoagulation treatment with warfarin or heparin, or require long-term antiplatelet therapy (aspirin ≥300 mg/day or clopidogrel ≥75 mg/day);
•Patients with active cardiovascular diseases within 6 months before treatment, including myocardial infarction, severe/uncontrolled angina. Echocardiography showing left ventricular ejection fraction \<50%, or poorly controlled arrhythmia;
•Known history of primary immunodeficiency virus infection;
•Patients with active or uncontrolled severe infections;
•Any other disease, clinically significant metabolic abnormalities, physical examination abnormalities, or laboratory test abnormalities, and based on the investigator's judgment, there is reasonable suspicion that the patient has a condition or disease that is unsuitable for the use of the study drug;
•Any situation that, in the investigator's opinion, could pose a risk to the patient receiving study drug treatment, interfere with the assessment of the study drug's safety, or affect the interpretation of results.

Arms & Interventions

Doxorubicin liposome combined with CapOX and Bevacizumab regimen as first-line treatment

6-month progression-free survival rate (6-month PFS rate) of Doxorubicin liposome combined with CapOX and Bevacizumab regimen as first-line treatment for advanced colorectal adenocarcinoma with SMAD4R361H/C mutation.

Intervention: Doxorubicin liposome combined with CapOX and Bevacizumab

Outcomes

Primary Outcomes

6-month progression-free survival (PFS)

Time Frame: 3 years

Defined as the time between the first occurrence of disease progression (PD) or death after the patient receives the study drug, whichever occurs first.